Rapport Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Rapport Therapeutics Inc in the second quarter 2026?
Rapport Therapeutics Inc recorded a cumulative net loss of $-137 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -29.02%.

Within the Major Pharmaceutical Preparations industry 113 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 2944, from total ROE ranking in the first quarter 2026 at 3541.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	60.5 %	64.96 %	58.68 %	58.34 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-137	-107	-111	-98	-88
Return On Equity (TTM)	-29.02 %	-24.79 %	-28.85 %	-28.6 %	-29.99 %
RAPP's Total Ranking	# 2944	# 3541	# 3065	# 3114	# 3065
Equity (TTM) in Millions	423	472	485	512	264
Seq. Equity Change	-10.3 %	-2.71 %	-5.27 %	94.15 %	-7.81 %
Seq. Net Income Change	-	-	-	-	-

Back to RAPP Management Effectiveness >> RAPP's 5 Years Annual ROE >> Compare RAPP ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 114
Sector	# 314
Overall	# 2944

Return On Equity Statistics
High	Average	Low
-24.79 %	-28.58 %	-33.33 %
(Mar 31 2026)		(Dec 31 2024)

News about Rapport Therapeutics Inc Return on Equity ROE

Breaking Barriers in Neurology RAP-219s Promising Voyage for Seizure Control and Beyond,

Recent developments in the clinical evaluation of RAP-219, an investigational treatment targeting focal onset seizures and central nervous system (CNS) disorders, have shown significant promise. Rapport Therapeutics has disclosed positive topline results from their Phase 2a clinical trial, underscoring RAP-219 s potential to transform treatment protocols for patients dealing with these health challenges. Phase 2a Clinical Trial Findings The Phase 2a study evaluated the efficacy and safety profile of RAP-219 in patients diagnosed with focal onset seizures. The trial s positive topline results highlight the drug s potential to reduce seizure frequency and severity effectively. According to the reported data, RAP-219 has demonstrated a consistent association between decreases in seizure biomarker measurements and meaningful reductions in clinical seizures. This correlation reinforces the therapeutic potential of RAP-219 as a significant advancement in the precision medicine approach for seizure management.

RAPP Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024
Total Equity in Millions	485	305	0	0	0
Y / Y Equity Change	58.68 %	-	-	-	-
Net Income in Millions	-111	-78	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-23 %	-25.64 %	-	-	-

Back to RAPP Management Effectiveness >> RAPP's 5 Years Annual ROE >> Compare RAPP ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RAPP's' Return on Equity at Yahoo Finance
RAPP's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RAPP's Competitors
Subscribers only: Roe for Rapport Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for RAPP's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-10T17:17:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.